Patients and medical societies are now official parties to administrative proceedings to reimburse rare disease medicines.

Aimed at expanding access to new products by streamlining the current nation-by-nation approach to post-regulatory approval adoption, the EU HTA regulation is one of the biggest shake-ups to the ...

In January 2025, a new unified and streamlined HTA framework, formalised under the EU Regulation on Health Technology Assessment (HTAR), was introduced. Its aim was to reduce the burden of ...

Drug pricing and reimbursement constraints are a major concern for the pharmaceutical industry. In order to balance ...

Regulatory fragmentation across the EU’s 27 countries and inadequate financing were holding back growth for startups, the ...

The EU's Ombudswoman said on Friday she had launched an inquiry into how the European Commission fashioned its recent ...

To achieve the European Green Deal's goal of 25% organic agriculture by 2030, researchers argue that new genomic techniques ...

The Council adopted today its negotiating position (general approach) on one of the proposals of the so-called ‘Omnibus I’ ...